Novartis announced that a late-stage study of its experimental meningitis B vaccine, 4CMenB, met all of its primary endpoints. The Swiss drugmaker noted the data, presented at the International Pathogenic Neisseria Conference (IPNC) in Banff, Canada, indicate that 4CMenB "has the potential to be the first broad-coverage vaccine" against the disease.
In the trial, which enrolled 3630 infants, the company reported that the majority of subjects who received the vaccine alongside their routine immunisations "achieved a robust immune response against all" meningococcal B antigens. The vaccine also "had an acceptable tolerability profile," the Swiss drugmaker noted.
Results from further clinical trials of 4CMenB are expected over the next few months, and Novartis said it plans to file for approval of the vaccine in Europe by the end of the year.
**Reference Articles
Meningitis vaccine meets late-stage study goals, Novartis says - (Bloomberg)
Novartis vaccine may guard against meningitis B - (Forexyard)
Novartis Phase III study shows meningococcal B vaccine candidate could be first to provide broad coverage against deadly disease - (Novartis)
**Published in "First World"
No comments:
Post a Comment